Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

BACKGROUND: Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) under development to prevent RSV infection in infants. Development and validation of methods to predict efficacious doses of neu...

Descripción completa

Detalles Bibliográficos
Autores principales: Maas, Brian M., Lommerse, Jos, Plock, Nele, Railkar, Radha A., Cheung, S.Y. Amy, Caro, Luzelena, Chen, Jingxian, Liu, Wen, Zhang, Ying, Huang, Qinlei, Gao, Wei, Qin, Li, Meng, Jie, Witjes, Han, Schindler, Emilie, Guiastrennec, Benjamin, Bellanti, Francesco, Spellman, Daniel S., Roadcap, Brad, Kalinova, Mariya, Fok-Seang, Juin, Catchpole, Andrew P., Espeseth, Amy S., Stoch, S. Aubrey, Lai, Eseng, Vora, Kalpit A., Aliprantis, Antonios O., Sachs, Jeffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603022/
https://www.ncbi.nlm.nih.gov/pubmed/34775220
http://dx.doi.org/10.1016/j.ebiom.2021.103651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603022/
https://www.ncbi.nlm.nih.gov/pubmed/34775220
http://dx.doi.org/10.1016/j.ebiom.2021.103651

Ejemplares similares